For decades, the treatment of depression has largely centered on one idea: serotonin.
Most antidepressants prescribed today—including SSRIs such as Prozac, Zoloft, Lexapro, and others—work by increasing serotonin levels in the brain. While these medications have helped millions of people, they don’t work for everyone. In fact, many individuals struggling with depression cycle through medication after medication with little relief.
This reality has led many psychiatrists, researchers, and patients to ask an important question:
What if depression isn’t primarily a serotonin problem?
That question is driving one of the most significant developments in psychiatry in recent decades: Spravato® (esketamine).
Today, Spravato is increasingly accepted as a treatment option for individuals living with treatment-resistant depression (TRD), and psychiatrists across the country are paying attention.
A Different Way of Thinking About Depression
The traditional serotonin theory of depression has been influential for more than 40 years. However, modern neuroscience suggests the story may be far more complex.
Researchers now believe that depression may involve changes in brain connectivity, neuroplasticity, inflammation, stress response systems, and glutamate signaling—the brain’s primary excitatory neurotransmitter.
This emerging understanding helps explain why some individuals continue to struggle despite trying multiple antidepressants. If depression is driven by factors beyond serotonin, treatments that target different pathways may be needed.
This is where Spravato enters the picture.
Unlike traditional antidepressants, Spravato works primarily through the glutamate system. Researchers believe this mechanism may help stimulate neuroplasticity—the brain’s ability to form new neural connections and adapt to change.
Many psychiatrists view this as a significant shift in how depression can be treated. Rather than simply increasing serotonin levels, Spravato may help create conditions that allow the brain to break out of entrenched depressive patterns and become more responsive to healing and recovery.
Why Spravato Has Generated So Much Interest
One reason psychiatrists are excited about Spravato is that it offers many patients with treatment-resistant depression something desperately needed: another option.
Treatment-resistant depression is generally defined as depression that has not adequately responded to at least two antidepressant trials. Unfortunately, this is far more common than many people realize.
Patients with treatment-resistant depression often describe years of persistent symptoms despite medication changes, therapy, lifestyle interventions, and countless attempts to feel better.
Many begin to wonder whether they will ever experience meaningful improvement.
Spravato was specifically approved by the FDA for treatment-resistant depression and has become one of the first truly novel antidepressant approaches introduced into mainstream psychiatry in decades.
Another reason for the excitement is its relatively rapid onset of action.
Traditional antidepressants often require four to eight weeks before meaningful improvement can be evaluated. Spravato works differently, and for some patients, improvements may begin to emerge much sooner.
This has been particularly important for patients experiencing severe depression or significant suicidal thinking, where waiting months for improvement can feel overwhelming.
Common Myths About Spravato and Ketamine
Despite growing acceptance, misconceptions about ketamine and Spravato remain common.
One of the biggest myths is that Spravato is simply a “party drug” repurposed for depression.
The reality is very different.
Spravato is an FDA-approved prescription medication that must be administered under strict medical supervision through a federally regulated Risk Evaluation and Mitigation Strategy (REMS) program. Patients are monitored during treatment, and the medication cannot be picked up at a pharmacy and taken at home.
Another misconception is that Spravato is experimental.
While ketamine has been used safely in medicine for decades, Spravato underwent extensive clinical trials before receiving FDA approval. Today, it is prescribed by psychiatrists throughout the United States and increasingly incorporated into standard treatment plans for individuals with treatment-resistant depression.
Some patients also worry that treatment involves “losing control” or having a frightening psychedelic experience.
While every person’s experience is unique, most patients describe the treatment as manageable and temporary. Many report feeling relaxed, reflective, or emotionally open during sessions. Importantly, treatment occurs in a safe medical environment with clinical staff available throughout the process.
As more mental health providers gain experience with Spravato and more patients benefit from treatment, many of the early misconceptions surrounding ketamine-based therapies continue to fade.
Insurance Coverage Is Expanding
Another major reason psychiatrists are increasingly recommending Spravato is its accessibility.
Several years ago, access to ketamine-based treatments was limited and often financially out of reach for many patients.
Today, the landscape looks very different.
Insurance companies are increasingly recognizing the evidence supporting Spravato for treatment-resistant depression. Many major insurers now offer coverage, including Medicare, Blue Cross Blue Shield plans, and Aetna.
For many eligible patients, out-of-pocket costs can be surprisingly low. In some cases, patients may have little to no out-of-pocket expense, depending on their insurance coverage and individual plan benefits.
This shift is important because treatment-resistant depression carries tremendous personal, emotional, and financial costs. When effective treatments become more accessible, more individuals have an opportunity to receive care that might otherwise have been unavailable.
The growing willingness of insurers to cover Spravato reflects a broader trend within psychiatry: this treatment is no longer viewed as a fringe or experimental option. It is becoming an established part of modern depression care.
What We’re Seeing at Innerbloom
At Innerbloom Ketamine Therapy, we’ve seen a noticeable increase in referrals from psychiatrists over the past several years.
Many psychiatrists are becoming more familiar with Spravato and increasingly recognize its value for appropriate patients who have struggled to find relief with traditional approaches.
What has been particularly encouraging is not just the rise in referrals but the outcomes we continue to observe.
Many patients referred to our clinic have already tried multiple antidepressants, psychotherapy, lifestyle changes, and other treatment strategies. These are often individuals who have spent years searching for answers.
While no treatment works for everyone, we have seen many patients experience meaningful improvements in mood, functioning, motivation, hopefulness, and quality of life after starting treatment.
Some patients report feeling like themselves again for the first time in years. Others describe being able to engage more effectively in therapy, reconnect with loved ones, return to activities they once enjoyed, or simply experience a reduction in the constant burden of depression.
A New Chapter in Depression Treatment
Just as the introduction of SSRIs transformed the treatment of depression decades ago, many clinicians believe that therapies targeting neuroplasticity and glutamate signaling mark the next major chapter in mental health care.
The growing enthusiasm for Spravato is not driven by hype. It stems from a combination of scientific research, real-world clinical experience, expanding insurance coverage, and patients’ experiences of finally finding relief after years of suffering.
Most importantly, Spravato offers something many individuals with treatment-resistant depression desperately need: hope.
If you or someone you love has struggled with depression despite multiple medications and treatment attempts, it may be worth speaking with your psychiatrist about whether Spravato could be an appropriate option.
The question is no longer simply, “Have you tried another antidepressant?”
Medical Disclaimer
All content on this website, including but not limited to this article, blog posts, testimonials, and FAQs, is not medical advice and should not be considered as such. This website cannot diagnose or treat any medical condition. Only a licensed medical professional who is familiar with you and your medical history can provide medical advice, diagnosis, or treatment.
The information provided here is for educational and informational purposes only. It is not intended to replace a consultation with a qualified healthcare provider. If you are experiencing symptoms of depression or any mental health condition, please consult with a licensed mental health professional or your primary care physician.
If you are in crisis or experiencing suicidal thoughts, please call the 988 Suicide and Crisis Lifeline (call or text 988) or go to your nearest emergency room immediately.
Innerbloom Ketamine Therapy cannot be held responsible or liable for any actions taken by those who access our website or rely on its content. Please refer to our Terms & Conditions for more information.
Has your antidepressant stopped working? Contact Innerbloom Ketamine Therapy at (805) 321-8471 or visit us at 100 Casa Street, Suite D3, San Luis Obispo, CA 93405.